

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: MADISON *et al.*
Serial No.: 10/099,700
Filed: March 13, 2002
Conf. No.: 4309
Cust. No.: 24961
For: *NUCLEIC ACID
MOLECULES ENCODING A
TRANSMEMBRANE
SERINE PROTEASE 7, THE
ENCODED POLYPEPTIDES
AND METHODS BASED
THEREON*
Art Unit: 1645
Examiner: Unassigned

RECEIVED

MAY 16 2003

TECH CENTER 1600/2900

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Transmitted herewith via hand delivery are an Supplemental Information Disclosure Statement, Form PTO-1449 (4 pages) and cited references for filing in connection with the above-identified application.

- [X] The Commissioner is hereby authorized to charge any fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 50-1213. A duplicate of this sheet is enclosed.

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:

Stephanie L. Seidman
Registration No. 33,779

Dated: May 14, 2003
Attorney Docket No. 24745-1613
Address all correspondence to:
Stephanie L. Seidman
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Madison *et al.*
Serial No.: 10/099,700
Filed: March 13, 2002
Conf. No.: 4309
Cust. No: 24961
For: *NUCLEIC ACID
MOLECULES ENCODING A
TRANSMEMBRANE
SERINE PROTEASE 7, THE
ENCODED POLYPEPTIDES
AND METHODS BASED
THEREON*
Art Unit: 1645
Examiner: Unassigned

#13
1593
6/30/03

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT IN ACCORDANCE
WITH 37 C.F.R. §§ 1.97-1.98**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Since this Information Disclosure Statement is filed before the receipt of a first Office Action on the merits for the above-captioned application, no filing fee is due. If it is determined that a fee is due, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-1213.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Supplemental Information

U.S.S.N. 10/099,700
MADISON, *et al.*
INFORMATION DISCLOSURE STATEMENT

Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Form PTO-1449 (4 pages) and copies of the cited documents are provided herewith.

The cited documents, listed on Forms PTO-1449 and supplied herewith, are in the English language, with the exception of item Q. This item, which is in the German language, is provided with an English language abstract (item AR). Hence, in accordance with the requirements of 37 C.F.R. § 1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Applicant also makes known to the Examiner the following U.S. and International applications, which are commonly owned and/or have one or more inventors in common:

<u>U.S.S.N.</u>	<u>Filing Date</u>	<u>Docket No.</u>
10/267,219	11/20/02	24745-1622
60/382,851	05/21/02	24745-P1624
60/394,347	07/02/02	24745-P1625
<u>Int'l App. No.</u>	<u>Filing Date</u>	<u>Docket No.</u>
PCT/US02/32417	10/08/02	24745-1621PC
PCT/US02/37626	11/20/02	24745-1622PC

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references, singly or in any combination thereof, is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.

U.S.S.N. 10/099,700
MADISON, *et al.*
INFORMATION DISCLOSURE STATEMENT

Applicant respectfully requests that the Examiner review the foregoing references and information and that they be made of record in the file history of the above-captioned application.

* * *

Respectfully submitted,
HELLER, EHRMAN, WHITE & McAULIFFE LLP

By:


Stephanie L. Seidman
Registration No. 33,779

Date: May 14, 2003
Attorney Docket No. 24745-1613
Address all correspondence to:
Stephanie L. Seidman
HELLER, EHRMAN, WHITE & McAULIFFE LLP
4350 La Jolla Village Drive, 7th floor
San Diego, CA 92122-1246
Telephone: (858) 450-8400
Facsimile: (858) 587-5360
EMAIL: sseidman@hewm.com

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 24745-1613	SERIAL NO. 10/099,700
	<div style="display: flex; justify-content: space-between; align-items: center;"> <div> APPLICANT Madison <i>et al.</i> </div> <div style="font-size: 2em; font-weight: bold; border: 1px solid black; padding: 5px;"> RECEIVED </div> </div>	
	FILING DATE March 13, 2002	GROUP MAY 16 2003 1645

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	NAME	CLASS	SUB CLASS	FILING DATE
	A	0	0	3	7	8	5	7	03/28/02	Semple <i>et al.</i>	514	19	12/17/00
	B	0	1	0	7	2	6	6	08/08/02	Lim-Wilby <i>et al.</i>	514	339	12/11/01
	C	0	1	6	0	9	6	2	10/31/02	Saksena <i>et al.</i>	514	19	07/19/01
	D	5	5	8	9	1	5	4	12/31/96	Anderson	424	1.41	11/22/94
	E	5	8	0	4	4	1	0	09/03/98	Yamaoka <i>et al.</i>	435	69.1	07/28/95
	F	6	2	9	4	6	6	3	09/25/01	O'Brien <i>et al.</i>	536	23.5	03/02/00

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation Yes No	
	G	0	0	1	2	7	0	8	03/09/00	PCT				
	H	0	0	5	0	0	6	1	08/31/00	PCT				
	I	0	0	5	2	0	4	4	09/08/00	PCT				
	J	0	0	5	3	7	5	6	09/14/00	PCT				
	K	0	0	5	5	1	2	4	09/21/00	PCT				
	L	0	0	6	8	2	4	7	11/16/00	PCT				
	M	0	0	7	8	9	6	1	12/28/00	PCT				
	N	0	1	0	4	1	4	1	01/18/01	PCT				
	O	0	1	4	9	8	6	4	07/12/01	PCT				
	P	0	1	6	8	8	4	8	09/20/01	PCT				
	Q	0	2	5	7	3	5	2	03/02/87	EP				X*
	R	0	2	0	0	8	1	87	01/31/02	PCT				
	S	0	2	0	0	8	6	0	01/03/02	PCT				
	T	0	2	0	4	8	0	97	06/20/02	PCT				
	U	0	2	0	7	2	7	86	09/19/02	PCT				
	V	0	2	0	7	7	2	63	10/03/02	PCT				

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)	ATTY. DOCKET NO. 24745-1613	SERIAL NO. 10/099,700
	APPLICANT Madison <i>et al.</i>	
	FILING DATE March 13, 2002	GROUP 1645

LIST OF PATENTS AND PUBLICATIONS FOR
APPLICANT'S INFORMATION DISCLOSURE
STATEMENT

RECEIVED

MAY 16 2003

TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER							DATE	COUNTRY	CLASS	SUB CLASS	Translation	
													Yes	No
	W	0	2	0	8	2	5	1	01/31/02	PCT				
	X	0	2	0	9	2	8	41	11/21/02	PCT				
	Y	0	2	0	9	5	0	07	11/28/02	PCT				
	Z	0	2	2	0	4	7	5	03/14/02	PCT				
	AA	0	3	0	0	4	6	81	01/16/03	PCT				
	AB	9	5	2	3	2	2	2	08/31/95	PCT				
	AC	9	6	3	0	3	5	3	10/03/96	PCT				
	AD	9	7	2	1	6	9	0	06/19/97	PCT				
	AE	9	9	1	7	7	9	0	04/15/99	PCT				
	AF	9	9	3	6	5	5	0	07/22/99	PCT				
	AG	9	9	4	2	1	2	0	08/26/99	PCT				
	AH	9	9	4	6	2	8	1	09/16/99	PCT				

X* = An English Language Derwent is Provided.

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

	AI	Database EMBL, Accession Number W22987, "Human Serine Protease 67", XP002169836 abstract, 8/Oct/97; abstract of Japan, <u>1997(10)</u> , 31/Oct/97; abstract of Japan 09 149790, 10/Jun/97
	AJ	Database EMBL, Accession Number AAY41710, "Human PR0618 protein sequence", <u>Genentech Inc.</u> , XP002175683 abstract, 7/Dec/99; PCT 99 46281 A, <u>Genentech Inc.</u> , 16/Sep/99
	AK	Database EMBL, Accession Number AAZ34033, "Human PR0618 nucleotide sequence", <u>Genentech Inc.</u> , XP002175684 abstract, 7/Dec/99; PCT 99 46281 A, <u>Genentech Inc.</u> , 16/Sep/99
	AL	Database EMBL, Accession Number AAZ33949, "Human PR0382 nucleotide sequence", <u>Genentech Inc.</u> , XP002175685 abstract, 7/Dec/99; PCT 99 46281 A, <u>Genentech Inc.</u> , 16/Sep/99

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)		ATTY. DOCKET NO. 24745-1613	SERIAL NO. 10/099,700
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT		APPLICANT Madison <i>et al.</i>	
		FILING DATE March 13, 2002	GROUP MAY 16 2003 1645

RECEIVED
TECH CENTER 1600/2900

AM	Database EMBL, Accession Number AAY41694, "Human PR0382 protein sequence", <u>Genentech Inc.</u> , XP002175687 abstract, 7/Dec/99; PCT 99 46281 A, <u>Genentech Inc.</u> , 16/Sep/99
AN	Database EMBL, Accession Number AI469095, "tm06c09.x1 Homo sapiens cDNA clone IMAGE:2155792", XP002175686 abstract, 17/Mar/99
AO	Database EMBL Accession number AF064819, October 28, 1999, J.C. Lang and D.E. Schuller: "Homo sapiens serine protease DESC1 MRNA", XP002166624, abstract
AP	Database EMBL Accession number R78581, June 10, 1995, L. Hillier et al.: "yi73c10.r1 Soares placenta Nb2HP Homo sapiens cDNA clone", XP002166677, abstract
AQ	Database EMBL Accession number Y99414, August 8, 2000, "Human PR01461", XP002166625, abstract
AR	Derwent# 007409639, WPI Acc. No.: 1988-043574/198807 for European Patent Application No. EP 257352, "Determining free portion of e.g. thyroxine in presence of binder - by reaction with antibody which does not effect bound-unbound equilibrium,".
AS	Fernandez <i>et al.</i> , "N-Succinyl-(β -alanyl-Lalanyl-L-leucyl)doxorubicin: An Extracellularly Tumor-Activated Prodrug Devoid of Intravenous Acute Toxicity," <i>J. Med. Chem.</i> <u>44(22)</u> : 3750-3753 (2001)
AT	Harris <i>et al.</i> , "Rapid and general profiling of protease specificity by using combinatorial fluorogenic substrate libraries," <i>Proc Natl Acad Sci USA</i> <u>97(14)</u> : 7754-7759 (2000)
AU	La Vallie <i>et al.</i> , "Cloning and Functional Expression of a cDNA Encoding the Catalytic Subunit of Bovine Enterokinase," <i>J. Biol. Chem.</i> <u>268(31)</u> :23311-23327 (1993)
AV	Lee, Sheau-Ling <i>et al.</i> , "Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease," <i>J. Biol. Chem.</i> <u>275(47)</u> : 36720-36725 (2000)
AW	Liu <i>et al.</i> , "Eradication of large colon tumor xenografts by targeted delivery of maytansinoids," <i>Proc Natl Acad Sci USA</i> <u>93</u> : 8618-8623 (1996)
AX	Lu <i>et al.</i> , "Bovine Proenteropeptidase Is Activated by Trypsin, and the Specificity of Enteropeptidase Depends on the Heavy Chain," <i>J. Biol. Chem.</i> <u>272(50)</u> :31293-31300 (1997)
AY	Rao <i>et al.</i> , "Partial Characterization of Matrix-Associated Serine Protease Inhibitors from Human Skin Cells," <i>J. Invest. Dermatol.</i> <u>104(3)</u> :379-383, (1995)
AZ	Pastan <i>et al.</i> , "Recombinant Toxins for Cancer Treatment," <i>Science</i> <u>254</u> :1173-1177 (1991)
BA	Schmidt <i>et al.</i> , "Targeted inhibition of tumour cell growth by a bispecific single-chain toxin containing an antibody domain and TGF α ," <i>Cancer</i> <u>74</u> :853-862 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 24745-1613	SERIAL NO. 10/099,700
	APPLICANT Madison <i>et al.</i> RECEIVED	
	FILING DATE March 13, 2002	GROUP 1645 MAY 16 2003

TECH CENTER 1600/2900

	BB	Trouet <i>et al.</i> , "Extracellularly Tumor-activated Prodrugs for the Selective Chemotherapy of Cancer: Application to Doxorubicin and Preliminary <i>in Vitro</i> and <i>in Vivo</i> Studies," <i>Cancer Research</i> <u>61</u> :2843-2846 (2001)
--	----	---

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.